Please login to the form below

Not currently logged in
Email:
Password:

Neurocrine Biosciences

This page shows the latest Neurocrine Biosciences news and features for those working in and with pharma, biotech and healthcare.

AbbVie’s blockbuster-in-waiting for endometriosis gets FDA nod

AbbVie’s blockbuster-in-waiting for endometriosis gets FDA nod

The approval is also good news for Neurocrine Biosciences, from which AbbVie in-licensed the drug in 2010 for $575 million.

Latest news

More from news
Approximately 2 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Royalty monetisation. 150. BIAL/ Neurocrine Biosciences. ONGENTYS (opicapone), COMT inhibitor for Parkinson's disease (approved in EU).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics